National Biobank Consortium of Taiwan Opening Ceremony of the Central Office （Oct.12,2020） Event Photos
石崇良次長致詞
梁賡義院長致詞
司徒惠康副院長介紹整合平台辦公室
Event Photo 1.
Event Photo 2.
Event Photo 3.
Event Photo 4.
Event Photo 5.
Event Photo 6.
Opening Ceremony of The Central Office of National Biobank Consortium of Taiwan
In recent years, with the advancement of precision medicine and emerging medical ecosystems, it has become a trend to conduct biomedical and genetic research with clinical information and biosamples, explore the multiple causes of diseases, and then introduce artificial intelligence and medical information to develop digital medicine. In response to this trend, the establishment of a good human biobank is an important key, and it is also to provide the most powerful resources for the development of digital medical and innovative technologies in the future. Since the "Biobank Management Act " was promulgated in 2010, there have been 33 Biobanks approved by the Ministry of Health and Welfare in Taiwan. In order to improve the efficiency of the use of the human biobanks in Taiwan, in 2019, the Executive Yuan commissioned the Ministry of Health and Welfare and the National Institutes of Health to establish the "National Biobank Consortium of Taiwan" （NBCT） with the purpose of establishing a complete biobank network to make use of the huge and reliable biomedical data resources to achieve the intention of promoting the development of the biotechnology and medical industry and improve the health and well-being of the people.
In order to make this consortium work effectively, the Central Office came into being. At the same time, there are two expert teams, namely the expert advisory committee and the review team, to assist in the promotion of the decision-making and case review affairs. Since the establishment of the NBCT in October, 2019, with the efforts of the Central Office in the past 11 months, it has successfully concluded contracts with 25 institutions’ human biodata databasebiobanks, and the number of registered cases has exceeded 310,000 （NBCT Website : https://nbct.nhri.org.tw/en/）. The content covers many popular diseases in Taiwan, such as lung cancer, liver cancer, colorectal cancer, breast cancer, oral cancer, and chronic diseases. In February , 2020, with the highest efficiency, a dedicated P2 level infectious disease Biobank was quickly established in the National Health Research Institutes Biobank, and collaborated with multiple medical institutions across North, Central and South of Tauwan. It has successfully collected 165 cases of severe special infectious pneumonia （COVID-19）. The blood samples become be available to researchers across Taiwan since April, 2020. As of September, 2020, 19 applications from industry, government, academia, and research have been received, including 8 applications from the industry, focusing on the development of rapid antibody detection technology. Among them, 13 applications have been reviewed and approved currently. Blood samples have been released one after another, and some of the industries already have obtained EUA approval for their products. The COVID-19 biobank has become a very important national public resources. The inauguration ceremony of the central office is held today. In the future, NBCT will continue to expand the application value. At the same time, it will also invite a number of academics and industry professionals to share their experiences.